Triple threat: radiation and immunotherapy join chemo against pancreatic cancer

NCT ID NCT07336953

Not yet recruiting Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase III trial tests whether adding targeted radiation and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with advanced pancreatic cancer live longer. About 198 participants who have not had prior treatment will be randomly assigned to receive either the standard chemo alone or the chemo plus radiation and immunotherapy. The main goal is to see if the combination improves overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gemcitabine, nab-paclitaxel, serplulimab, and stereotactic body radiation therapy
What this could lead to: If successful, this combination could offer a new first-line treatment option that extends survival for people with advanced pancreatic cancer.
What could go wrong: This is an early-stage Phase III trial, so results are not guaranteed. Adding radiation and immunotherapy may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PDAC - PANCREATIC DUCTAL ADENOCARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.